![Thorvald Nagel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Thorvald Nagel
Direttore/Membro del Consiglio presso
IMMUNIC, INC.
Profilo
Mr. Thorvald Nagel is an Independent Director at Immunic, Inc. and an Analyst at BVF Partners LP.
He is on the Board of Directors at Immunic, Inc.
Mr. Nagel was previously employed as a Senior Analyst by Monashee Investment Management LLC, an Associate by Stifel Financial Corp., and a Senior Analyst by Clearview Healthcare Partners LLC.
He received his undergraduate degree from Vanderbilt University and a graduate degree from the University of Notre Dame.
Posizioni attive di Thorvald Nagel
| Società | Posizione | Inizio |
|---|---|---|
| IMMUNIC, INC. | Direttore/Membro del Consiglio | 12/02/2026 |
BVF Partners LP
 BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Analyst-Equity | 01/07/2023 |
Precedenti posizioni note di Thorvald Nagel
| Società | Posizione | Fine |
|---|---|---|
Monashee Investment Management LLC
 Monashee Investment Management LLC Investment ManagersFinance Monashee seeks to provide consistently stronger returns than the broader equity markets by investing systematically in the equity and convertible debt securities of companies raising new equity capital globally or via secondary offerings, block trades, registered direct offerings and PIPEs where a significant shareholder seeks to sell a secondary position. The firm will seek to capture the discount inherent in equity new issues, including both offerings by companies that are already publicly traded (follow-ons) and initial public offerings (IPOs). | Analyst-Equity | 01/07/2023 |
| STIFEL FINANCIAL CORP. | Corporate Officer/Principal | 01/06/2021 |
Clearview Healthcare Partners LLC
 Clearview Healthcare Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services in life sciences | Corporate Officer/Principal | 01/09/2020 |
Formazione di Thorvald Nagel
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
54
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Stifel Financial Corp.
 Stifel Financial Corp. Investment ManagersFinance Operates as a bank holding company through its subsidiaries provides wealth and asset management, investment banking & trading services | Finance |
BVF Partners LP
BVF Partners LP Investment ManagersFinance BVF generally pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The focus of the BVF strategy is on fundamental, bottom-up analysis of individual issuers based on the theory that market mispricing exist because market prices do not incorporate all knowable economic and other relevant data. | Finance |
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monashee Investment Management LLC
Monashee Investment Management LLC Investment ManagersFinance Monashee seeks to provide consistently stronger returns than the broader equity markets by investing systematically in the equity and convertible debt securities of companies raising new equity capital globally or via secondary offerings, block trades, registered direct offerings and PIPEs where a significant shareholder seeks to sell a secondary position. The firm will seek to capture the discount inherent in equity new issues, including both offerings by companies that are already publicly traded (follow-ons) and initial public offerings (IPOs). | Finance |
Immunic, Inc.
 Immunic, Inc. Pharmaceuticals: MajorHealth Technology Develops oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases | Health Technology |
Clearview Healthcare Partners LLC
Clearview Healthcare Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides strategy consulting services in life sciences | Commercial Services |
